Key result
The AP-pVP1 nanovaccine showed 1.8-fold higher enrichment in draining lymph nodes and elicited a cytotoxicity response 31% and 90% higher than PA-pVP1 and P-pVP1 groups, respectively.
The AP-pVP1 nanovaccine effectively targets draining lymph nodes and enhances immunogenicity against viral myocarditis in an in vivo model.
Answers are grounded in this paper and cite their sources.
Advances lymph node-targeted nanovaccines in preclinical viral myocarditis models; leaves open human translation.
In this study, we engineered two recombinant fusion proteins by conjugating the streptococcal albumin-binding domain (ABD) to either the N-terminus (AP) or C-terminus (PA) of protamine (P). These proteins spontaneously assembled with the CVB3 VP1 DNA vaccine (pVP1) into nanovaccines, leveraging ABD's albumin-binding capacity to target draining lymph nodes (dLNs) and enhance immunogenicity and efficacy. All recombinant AP, PA, and P proteins efficiently bound to and protected the pVP1 plasmid, forming nanoparticles with a diameter of 170-200 nm. In vivo distribution assays showed that AP-pVP1 enrichment was approximately 1.8-fold higher than that of PA-pVP1 and P-pVP1. Following intramuscular immunization, the AP-pVP1 group showed the highest levels of CVB3-specific neutralizing serum IgG. The cytotoxicity response was approximately 31% and 90% higher than the PA-pVP1 and P-pVP1 groups, respectively. The percentage of IFN-γ
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Viral myocarditis. AP-pVP1 nanovaccine vs. PA-pVP1 and P-pVP1 was evaluated on CVB3-specific neutralizing serum IgG and cytotoxicity response. The AP-pVP1 nanovaccine showed 1.8-fold higher enrichment in draining lymph nodes and elicited a cytotoxicity response 31% and 90% higher than PA-pVP1 and P-pVP1 groups, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: